ClinicalTrials.gg
CompletedNCT05604872Updated Nov 3, 2022

Association Between ORA and Residual Refractive Astigmatism After SMILE

An observational study in Refractive Errors and Astigmatism, sponsored by Taipei Nobel Eye Clinic. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-11-03.

Primary conditionAstigmatismRegistry: Refractive ErrorsReclassifiedWhy we changed it
Registry
Refractive Errors — the first condition term the registry derived for this study.
ClinicalTrials.gg
Astigmatism
Why
  1. The study's listed conditions name Astigmatism, a narrower term within Refractive Errors.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Taipei Nobel Eye Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
530
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The aim of our study is to analysis and compare the relationship between ORA and postoperative astigmatism in low astigmatism (less than 1D) and moderate to high (1D to 3D) astigmatism patients after SMILE (Small Incision Lenticule Extraction) refractive surgery.

02

Conditions studied

  • Refractive Errors
  • Astigmatism

Browse trials for

03

In context

Astigmatism Reclassified

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

This study's enrollment of 530 is above the median of 100 across 82 observational studies indexed under Astigmatism.

Browse Astigmatism studies →

Lead sponsor

Taipei Nobel Eye Clinic is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Astigmatism, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Refractive Errors. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study was conducted by retrospective chart review in Taipei Nobel Eye Clinic from 2020 to 2022.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Corrected distance visual acuity of both eyes reaches 0.1 logarithm of the minimum angle of resolution (logMAR)
  • Stable refractive errors of myopia and astigmatism who received SMILE refractive surgery of both eyes

Exclusion criteria

Exclusion Criteria:

  • Cataract
  • Corneal opacities or irregularities
  • Dry eye (Schirmer's test I ≤ 5mm)
  • Amblyopia
  • Coexisting ocular pathologies
  • Glaucoma
  • Non-dilating pupil
  • History of intraocular surgery, laser therapy, or retinopathy
  • Optic nerve or macular diseases
  • Estimated postoperative cornea residual stromal thickness less than 250 μm
  • Pregnancy or under lactation
  • Uncontrolled diabetic mellitus or systemic immune disease _Refusal or unable to maintain follow-up
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
530 participants (actual)
Patient registry
No

Interventions

  • ProcedureSmall Incision Lenticule Extraction

    A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions

06

What researchers measure

Primary outcomes

  1. Corrected distance visual acuity

    in LogMAR unit

    Time frame: 3 months after surgery

  2. Manifest refraction

    in Diopter

    Time frame: 3 months after surgery

07

Study locations

1 site
  • Taipei Nobel Eye Clinic
    Taipei, Taiwan
08

References and documents

Publications

  • Gyldenkerne A, Hjortdal J, Ivarsen A. Astigmatism prediction in small-incision lenticule extraction. J Cataract Refract Surg. 2020 Apr;46(4):524-533. doi: 10.1097/j.jcrs.0000000000000083. PubMed 32271519 ↗
  • Jun I, Kang DSY, Arba-Mosquera S, Reinstein DZ, Archer TJ, Jean SK, Kim EK, Seo KY, Lee HK, Kim TI. Comparison of clinical outcomes between vector planning and manifest refraction planning in SMILE for myopic astigmatism. J Cataract Refract Surg. 2020 Aug;46(8):1149-1158. doi: 10.1097/j.jcrs.0000000000000100. PubMed 32347695 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jun 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Nov 3, 2022
StartActual
Jun 1, 2020
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05604872
Lead sponsor
Taipei Nobel Eye Clinic
Responsible party
Chao-Kai Chang (Dean, Taipei Nobel Eye Clinic) — Principal investigator
First posted
Nov 3, 2022
Start date
Jun 1, 2020
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Nov 3, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion